UNSPSC 51131704: Urokinase

This classification denotes a plasminogen activator with the molecular formula C1376H2145N383O406S18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83G67E21XI, more generally known as urokinase. European Medicines Agency schedules urokinase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05055MIG. The term UROKINASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 21 no. 12 1967, list 7.

UROKINASE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule urokinase under HS 35079090 and SITC 51691. As of Q4 2014, UROKINASE remains the US FDA Preferred Term for this commodity. SMILES: NONE.

UNSPSC 51131704 Urokinase is a Commodity code that nominally covers thrombolytic pharmaceutical products, but the recent state and local activity recorded under this code does not reflect actual urokinase procurement. Sourcewell, a Minnesota local government unit and service cooperative, posted RFP #061626 on May 12, 2026 with a June 16, 2026 response deadline to establish a contracting solution for law enforcement equipment — a scope entirely unrelated to pharmaceutical thrombolytics. The mismatch suggests either a coding error in the state or local source system or a misattribution in the available record. State and local governments do procure thrombolytic and other emergency pharmaceuticals through hospital systems, public health departments, and emergency medical services, but the single recent opportunity indexed under this code reflects law enforcement equipment procurement rather than pharmaceutical supply.

Sourcewell's RFP #061626 targets a multi-jurisdiction cooperative purchasing vehicle spanning Franklin, Grant, Grays Harbor, Chelan, and Yakima Counties in Washington, plus numerous other public entities across the United States and Canada. The solicitation is structured to serve thousands of governmental agencies, higher education institutions, K–12 school districts, nonprofits, and tribal governments through a participating addendum framework. With no concrete pharmaceutical opportunities in the recent record and the single indexed opportunity falling outside the code's stated scope, the code shows little actionable activity for vendors pursuing actual urokinase or thrombolytic supply to state and local entities.